Calidi Biotherapeutics Inc. Total Assets
Calidi Biotherapeutics Inc. total assets. Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) holds total assets worth $8.86 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Calidi Biotherapeutics Inc. (CLDI) total market value for the company's overall valuation and market capitalisation.
Total Assets of Calidi Biotherapeutics Inc. (2020–2025)
Total assets of Calidi Biotherapeutics Inc. from 2020 to 2025. This chart illustrates how Calidi Biotherapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See Calidi Biotherapeutics Inc. stock quote for real-time trading data and today's change.
Calidi Biotherapeutics Inc. - Asset Composition Analysis
Calidi Biotherapeutics Inc. Total Assets Breakdown (December 2025)
Calidi Biotherapeutics Inc. total assets breakdown as of December 2025. Calidi Biotherapeutics Inc.'s total assets of $8.86 Million consist of 70.6% current assets and 29.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 63.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Calidi Biotherapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Calidi Biotherapeutics Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Calidi Biotherapeutics Inc.'s current assets represent 70.6% of total assets in 2025, an increase from 27.7% in 2020.
- Cash Position: Cash and equivalents constituted 63.2% of total assets in 2025, up from 22.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Calidi Biotherapeutics Inc. Competitors by Total Assets
Key competitors of Calidi Biotherapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Calidi Biotherapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 1.08 | 0.17 |
| Quick Ratio | 1.59 | 1.08 | 0.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.32 Million | $731.00K | $-565.68K |
Calidi Biotherapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Calidi Biotherapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -37.5% |
| Total Assets | $8.86 Million |
| Market Capitalization | $2.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Calidi Biotherapeutics Inc.'s assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Calidi Biotherapeutics Inc.'s assets decreased by 37.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Calidi Biotherapeutics Inc. (2020–2025)
The table below shows the annual total assets of Calidi Biotherapeutics Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.86 Million | -37.55% |
| 2024-12-31 | $14.18 Million | +41.55% |
| 2023-12-31 | $10.02 Million | +285.79% |
| 2022-12-31 | $2.60 Million | -23.41% |
| 2021-12-31 | $3.39 Million | +83.10% |
| 2020-12-31 | $1.85 Million | -- |
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast ca… Read more